{
    "Rank": 426,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT03263780",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "IIT2016-19-DASKIVICH-18F"
                },
                "Organization": {
                    "OrgFullName": "Cedars-Sinai Medical Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "High Resolution PET-MRI Before Prostate Cancer HIFU",
                "OfficialTitle": "High-Resolution, 18F-fluciclovine PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy"
            },
            "StatusModule": {
                "StatusVerifiedDate": "February 2021",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "December 7, 2017",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "January 8, 2020",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "January 8, 2020",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "August 22, 2017",
                "StudyFirstSubmitQCDate": "August 22, 2017",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "August 28, 2017",
                    "StudyFirstPostDateType": "Actual"
                },
                "ResultsFirstSubmitDate": "December 17, 2020",
                "ResultsFirstSubmitQCDate": "February 2, 2021",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "February 21, 2021",
                    "ResultsFirstPostDateType": "Actual"
                },
                "ResultsFirstPostedQCCommentsDateStruct": {
                    "ResultsFirstPostedQCCommentsDate": "January 13, 2021",
                    "ResultsFirstPostedQCCommentsDateType": "Actual"
                },
                "LastUpdateSubmitDate": "February 2, 2021",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "February 21, 2021",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor-Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Timothy J. Daskivich",
                    "ResponsiblePartyInvestigatorTitle": "Staff Physician I, Division of Urology; Urologic Oncologist; Director, Health Services Research, Department of Surgery Cedars Sinai Medical Center",
                    "ResponsiblePartyInvestigatorAffiliation": "Cedars-Sinai Medical Center"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Timothy J. Daskivich",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Blue Earth Diagnostics",
                            "CollaboratorClass": "INDUSTRY"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes",
                "IsFDARegulatedDrug": "Yes",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "This prospective trial aims to determine if enhanced prostate imaging using two novel imaging technologies (high resolution DWI and 18F-fluciclovine PET-MRI) will detect prostate cancers not seen on standard multiparametric prostate MRI in patients considered candidates for focal HIFU.",
                "DetailedDescription": "This is a prospective trial to evaluate the effectiveness of 18F-fluciclovine PET-hrMRI versus standard mpMRI at identifying prostate cancer targets for HIFU therapy.\n\nParticipants with clinically localized, unilateral high grade prostate cancer (Gleason score 7-10 prostate cancer localized to one lobe on prior biopsies) OR at high risk for having unrecognized high grade prostate cancer (overall Gleason score 6 with > half of systematic biopsy cores positive and > 50% of core involvement in at least one core), interested in HIFU would receive both a standard mpMRI and 18F-fluciclovine PET-hrMRI.\n\nParticipants would then undergo a mapping biopsy using a standard sextant template plus MRI/US-fusion targeted biopsy of any lesion suspicious lesion on mpMRI or PET-hrMRI."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Prostate Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Diagnostic imaging",
                        "High-Intensity Focused Ultrasound",
                        "HIFU",
                        "18F-Fluciclovine",
                        "high resolution diffusion-weighted imaging"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Other",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "21",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "18F-Fluciclovine",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "10mCi +/-20% 18F-fluciclovine injection",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: 18F-Fluciclovine"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "18F-Fluciclovine",
                            "InterventionDescription": "Imaging (comparing standard and experimental high resolution diffusion-weighted imaging [DWI] MRI with 18F-Fluciclovine)",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "18F-Fluciclovine"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Axumin",
                                    "prostate-cancer-specific radiotracer"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Number of Biopsy-proven Cancers (Gleason 6+) That Standard Imaging (mpMRI) Would Have Missed Compared With High Resolution Diffusion-weighted Imaging (DWI) PET-hrMRI on Mapping MRI.",
                            "PrimaryOutcomeDescription": "A Gleason score of 6 is low grade, 7 is intermediate grade, and a score of 8 to 10 is high grade cancer. The Prostate Imaging Reporting and Data System (PI-RADS) is used to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious). Difference between sensitivities to identify prostate lesions. This is analyzed by the number of biopsy-proven cancerous zones (Gleason 6+) that mpMRI missed compared to PET or hrMRI (PIRADS) compared as follows:\n\nmpMRI vs hrMRI and PET (PIRADS 3-5 & Gleason 7+) mpMRI vs hrMRI or PET (PIRADS 3-5 & Gleason 7+)\n\nmpMRI vs hrMRI and PET (PIRADS 4-5 & Gleason 7+) mpMRI vs hrMRI or PET (PIRADS 4-5 & Gleason 7+)\n\nmpMRI vs hrMRI and PET (PIRADS 3-5 & Gleason 6+) mpMRI vs hrMRI or PET (PIRADS 3-5 & Gleason 6+)\n\nmpMRI vs hrMRI and PET (PIRADS 4-5 & Gleason 6+) mpMRI vs hrMRI or PET (PIRADS 4-5 & Gleason 6+)",
                            "PrimaryOutcomeTimeFrame": "At time of post-imaging biopsy"
                        },
                        {
                            "PrimaryOutcomeMeasure": "Number of Biopsy-proven Cancers (Gleason 7+) That Standard Imaging (mpMRI) Would Have Missed Compared With High Resolution Diffusion-weighted Imaging (DWI) PET-hrMRI on Mapping MRI.",
                            "PrimaryOutcomeDescription": "A Gleason score of 6 is low grade, 7 is intermediate grade, and a score of 8 to 10 is high grade cancer. The Prostate Imaging Reporting and Data System (PI-RADS) is used to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious). Difference between sensitivities to identify prostate lesions. This is analyzed by the number of biopsy-proven cancerous zones (Gleason 7+) that mpMRI missed compared to PET or hrMRI (PIRADS) compared as follows:\n\nmpMRI vs hrMRI and PET (PIRADS 3-5 & Gleason 7+) mpMRI vs hrMRI or PET (PIRADS 3-5 & Gleason 7+)\n\nmpMRI vs hrMRI and PET (PIRADS 4-5 & Gleason 7+) mpMRI vs hrMRI or PET (PIRADS 4-5 & Gleason 7+)\n\nmpMRI vs hrMRI and PET (PIRADS 3-5 & Gleason 6+) mpMRI vs hrMRI or PET (PIRADS 3-5 & Gleason 6+)\n\nmpMRI vs hrMRI and PET (PIRADS 4-5 & Gleason 6+) mpMRI vs hrMRI or PET (PIRADS 4-5 & Gleason 6+)",
                            "PrimaryOutcomeTimeFrame": "At time of post-imaging biopsy"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Negative Biopsy Rate (Number of Participants With Negative Biopsy)",
                            "SecondaryOutcomeDescription": "A Gleason score of 6 is low grade, 7 is intermediate grade, and a score of 8 to 10 is high grade cancer. The Prostate Imaging Reporting and Data System (PI-RADS) is used to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious). Following the tumor mapping study, patients with high grade disease (i.e. Gleason grade 4 or 5) in one lobe undergo hemigland or focal HIFU of that lobe. Patients would then undergo repeat prostate biopsy to assess the negative biopsy rate in the treated region.",
                            "SecondaryOutcomeTimeFrame": "6 months following standard HIFU therapy"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Rate of High Grade Cancer (Number of Patients With High Grade Cancer)",
                            "SecondaryOutcomeDescription": "A Gleason score of 6 is low grade, 7 is intermediate grade, and a score of 8 to 10 is high grade cancer. The Prostate Imaging Reporting and Data System (PI-RADS) is used to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious). Following the tumor mapping study, patients with high grade disease (i.e. Gleason grade 4 or 5) in one lobe undergo hemigland or focal HIFU of that lobe. Patients would then undergo repeat prostate biopsy to assess the absence of Gleason grade 4 or 5 in the untreated region.",
                            "SecondaryOutcomeTimeFrame": "6 months following standard HIFU therapy"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nProstate biopsy consisting of \u2265 10 tissue cores sampled\nPSA </=20 ng/mL\ncT1-cT2c\nEither overall gleason score >/= 7 with Gleason grade 4 or 5 component localized to one lobe (i.e. right or left) OR overall Gleason score 6 with >/= half of systematic biopsy cores positive and >/= 50% of core involvement in at least one core\nPatient considering focal HIFU therapy\n\nExclusion Criteria:\n\nPrevious local therapy for prostate cancer\nInability to receive PET tracer\nInability to receive MRI\nSuggestion of extracapsular extension or seminal vesicle invasion on imaging\nEstimated creatinine clearance <45 mL/min (Cockcroft-Gault equation)\nAny other condition which, in the investigator's option, may make the patient a poor candidate for participation in a clinical trial.",
                "HealthyVolunteers": "No",
                "Gender": "Male",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Timothy Daskivich, MD",
                            "OverallOfficialAffiliation": "Cedars-Sinai Medical Center",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Cedars-Sinai Medical Center",
                            "LocationCity": "Los Angeles",
                            "LocationState": "California",
                            "LocationZip": "90048",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowRecruitmentDetails": "Opened to accrual on 12/07/2017 with first subject enrolled on study 12/18/2017. A total of 21 patients consented, one withdrew consent prior to intervention and was replaced, 13 were evaluable for primary outcome measure, however 11 subjects of the total target accrual of 20 subjects completed study with the last subject off treatment/off study as of 1/8/2020.",
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "18F-Fluciclovine",
                            "FlowGroupDescription": "10mCi +/-20% 18F-fluciclovine injection\n\n18F-Fluciclovine: Imaging (comparing standard and experimental high resolution diffusion-weighted imaging [DWI] MRI with 18F-Fluciclovine)\n\nPrior to HIFU therapy, all subjects undergo mapping MRI using both standard mpMRI and experimental diffusion-weighted imaging (DWI) PET-hrMRI with 18F-Fluciclovine. PET scans involve injection of the radioisotope or tracer, where all subjects will receive 10mCi +/-20% 18F-fluciclovine injection, diluted up to 10mL injected via the IV, as an IV bolus injection followed by 10mL flush with normal saline solution."
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "21"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementComment": "13 evaluable for primary outcome, but 11 total completed study.",
                                                    "FlowAchievementNumSubjects": "11"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "10"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "FlowDropWithdrawList": {
                                "FlowDropWithdraw": [
                                    {
                                        "FlowDropWithdrawType": "Withdrawal by Subject",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "3"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Ineligible (incomplete post-HIFU)",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "7"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "18F-Fluciclovine",
                            "BaselineGroupDescription": "10mCi +/-20% 18F-fluciclovine injection\n\n18F-Fluciclovine: Imaging (comparing standard and experimental high resolution diffusion-weighted imaging [DWI] MRI with 18F-Fluciclovine)"
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "13"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Categorical",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "<=18 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Between 18 and 65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "3"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": ">=65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "10"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Age, Continuous",
                            "BaselineMeasureParamType": "Median",
                            "BaselineMeasureDispersionType": "Full Range",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "70",
                                                                "BaselineMeasurementLowerLimit": "51",
                                                                "BaselineMeasurementUpperLimit": "77"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Age, Continuous",
                            "BaselineMeasureParamType": "Mean",
                            "BaselineMeasureDispersionType": "Standard Deviation",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "67.8",
                                                                "BaselineMeasurementSpread": "7.54"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "13"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Ethnicity (NIH/OMB)",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Hispanic or Latino",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Not Hispanic or Latino",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "13"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Unknown or Not Reported",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Race (NIH/OMB)",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Asian",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Black or African American",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "White",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "10"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "More than one race",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Unknown or Not Reported",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Region of Enrollment",
                            "BaselineMeasureParamType": "Number",
                            "BaselineMeasureUnitOfMeasure": "participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineClassTitle": "United States",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "13"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Number of Biopsy-proven Cancers (Gleason 6+) That Standard Imaging (mpMRI) Would Have Missed Compared With High Resolution Diffusion-weighted Imaging (DWI) PET-hrMRI on Mapping MRI.",
                            "OutcomeMeasureDescription": "A Gleason score of 6 is low grade, 7 is intermediate grade, and a score of 8 to 10 is high grade cancer. The Prostate Imaging Reporting and Data System (PI-RADS) is used to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious). Difference between sensitivities to identify prostate lesions. This is analyzed by the number of biopsy-proven cancerous zones (Gleason 6+) that mpMRI missed compared to PET or hrMRI (PIRADS) compared as follows:\n\nmpMRI vs hrMRI and PET (PIRADS 3-5 & Gleason 7+) mpMRI vs hrMRI or PET (PIRADS 3-5 & Gleason 7+)\n\nmpMRI vs hrMRI and PET (PIRADS 4-5 & Gleason 7+) mpMRI vs hrMRI or PET (PIRADS 4-5 & Gleason 7+)\n\nmpMRI vs hrMRI and PET (PIRADS 3-5 & Gleason 6+) mpMRI vs hrMRI or PET (PIRADS 3-5 & Gleason 6+)\n\nmpMRI vs hrMRI and PET (PIRADS 4-5 & Gleason 6+) mpMRI vs hrMRI or PET (PIRADS 4-5 & Gleason 6+)",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "Total biopsy-proven cancers (Gleason 6+)",
                            "OutcomeMeasureTimeFrame": "At time of post-imaging biopsy",
                            "OutcomeMeasureTypeUnitsAnalyzed": "Total biopsy-proven cancers (Gleason 6+)",
                            "OutcomeMeasureDenomUnitsSelected": "Total biopsy-proven cancers (Gleason 6+)",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "18F-Fluciclovine",
                                        "OutcomeGroupDescription": "10mCi +/-20% 18F-fluciclovine injection\n\n18F-Fluciclovine: Imaging (comparing standard and experimental high resolution diffusion-weighted imaging [DWI] MRI with 18F-Fluciclovine)\n\nPrior to HIFU therapy, all subjects undergo mapping MRI using both standard mpMRI and experimental diffusion-weighted imaging (DWI) PET-hrMRI with 18F-Fluciclovine. PET scans involve injection of the radioisotope or tracer, where all subjects will receive 10mCi +/-20% 18F-fluciclovine injection, diluted up to 10mL injected via the IV, as an IV bolus injection followed by 10mL flush with normal saline solution."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "13"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeDenomUnits": "Total biopsy-proven cancers (Gleason 6+)",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "32"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "Number of biopsy-proven cancers (Gleason 6+) that mpMRI missed compared to PET or hrMRI (PIRADS 3-5)",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "5"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Number of biopsy-proven cancers (Gleason 6+) that mpMRI missed compared to PET & hrMRI (PIRADS 3-5)",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Number of biopsy-proven cancers (Gleason 6+) that mpMRI missed compared to PET or hrMRI (PIRADS 4-5)",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "4"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Number of biopsy-proven cancers (Gleason 6+) that mpMRI missed compared to PET & hrMRI (PIRADS 4-5)",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeAnalysisList": {
                                "OutcomeAnalysis": [
                                    {
                                        "OutcomeAnalysisGroupIdList": {
                                            "OutcomeAnalysisGroupId": [
                                                "OG000"
                                            ]
                                        },
                                        "OutcomeAnalysisGroupDescription": "mpMRI vs hrMRI and PET (PIRADS 3-5 & Gleason 6+)",
                                        "OutcomeAnalysisNonInferiorityType": "Superiority",
                                        "OutcomeAnalysisPValue": "0.056",
                                        "OutcomeAnalysisPValueComment": "mpMRI vs hrMRI and PET (PIRADS 3-5 & Gleason 6+)",
                                        "OutcomeAnalysisStatisticalMethod": "Durkalski's Chi-square test",
                                        "OutcomeAnalysisParamType": "Sensitivity",
                                        "OutcomeAnalysisParamValue": "0.25",
                                        "OutcomeAnalysisCIPctValue": "95",
                                        "OutcomeAnalysisCINumSides": "2-Sided",
                                        "OutcomeAnalysisCILowerLimit": "0.19",
                                        "OutcomeAnalysisCIUpperLimit": "0.46",
                                        "OutcomeAnalysisEstimateComment": "We did not present standard deviation as the variability is already incorporated in the provided confidence interval."
                                    },
                                    {
                                        "OutcomeAnalysisGroupIdList": {
                                            "OutcomeAnalysisGroupId": [
                                                "OG000"
                                            ]
                                        },
                                        "OutcomeAnalysisGroupDescription": "mpMRI vs hrMRI or PET (PIRADS 3-5 & Gleason 6+)",
                                        "OutcomeAnalysisNonInferiorityType": "Superiority",
                                        "OutcomeAnalysisPValue": "0.56",
                                        "OutcomeAnalysisPValueComment": "mpMRI vs hrMRI or PET (PIRADS 3-5 & Gleason 6+)",
                                        "OutcomeAnalysisStatisticalMethod": "Durkalski's Chi-square test",
                                        "OutcomeAnalysisParamType": "Sensitivity",
                                        "OutcomeAnalysisParamValue": "0.56",
                                        "OutcomeAnalysisCIPctValue": "95",
                                        "OutcomeAnalysisCINumSides": "2-Sided",
                                        "OutcomeAnalysisCILowerLimit": "0.44",
                                        "OutcomeAnalysisCIUpperLimit": "0.78",
                                        "OutcomeAnalysisEstimateComment": "We did not present standard deviation as the variability is already incorporated in the provided confidence interval."
                                    },
                                    {
                                        "OutcomeAnalysisGroupIdList": {
                                            "OutcomeAnalysisGroupId": [
                                                "OG000"
                                            ]
                                        },
                                        "OutcomeAnalysisGroupDescription": "mpMRI vs hrMRI and PET (PIRADS 4-5 & Gleason 6+)",
                                        "OutcomeAnalysisNonInferiorityType": "Superiority",
                                        "OutcomeAnalysisPValue": "0.060",
                                        "OutcomeAnalysisPValueComment": "mpMRI vs hrMRI and PET (PIRADS 4-5 & Gleason 6+)",
                                        "OutcomeAnalysisStatisticalMethod": "Durkalski's Chi-square test",
                                        "OutcomeAnalysisParamType": "Sensitivity",
                                        "OutcomeAnalysisParamValue": "0.22",
                                        "OutcomeAnalysisCIPctValue": "95",
                                        "OutcomeAnalysisCINumSides": "2-Sided",
                                        "OutcomeAnalysisCILowerLimit": "0.17",
                                        "OutcomeAnalysisCIUpperLimit": "0.47",
                                        "OutcomeAnalysisEstimateComment": "We did not present standard deviation as the variability is already incorporated in the provided confidence interval."
                                    },
                                    {
                                        "OutcomeAnalysisGroupIdList": {
                                            "OutcomeAnalysisGroupId": [
                                                "OG000"
                                            ]
                                        },
                                        "OutcomeAnalysisGroupDescription": "mpMRI vs hrMRI or PET (PIRADS 4-5 & Gleason 6+)",
                                        "OutcomeAnalysisNonInferiorityType": "Superiority",
                                        "OutcomeAnalysisPValue": "0.083",
                                        "OutcomeAnalysisPValueComment": "mpMRI vs hrMRI or PET (PIRADS 4-5 & Gleason 6+)",
                                        "OutcomeAnalysisStatisticalMethod": "Durkalski's Chi-square test",
                                        "OutcomeAnalysisParamType": "Sensitivity",
                                        "OutcomeAnalysisParamValue": "0.50",
                                        "OutcomeAnalysisCIPctValue": "95",
                                        "OutcomeAnalysisCINumSides": "2-Sided",
                                        "OutcomeAnalysisCILowerLimit": "0.39",
                                        "OutcomeAnalysisCIUpperLimit": "0.74",
                                        "OutcomeAnalysisEstimateComment": "We did not present standard deviation as the variability is already incorporated in the provided confidence interval."
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Number of Biopsy-proven Cancers (Gleason 7+) That Standard Imaging (mpMRI) Would Have Missed Compared With High Resolution Diffusion-weighted Imaging (DWI) PET-hrMRI on Mapping MRI.",
                            "OutcomeMeasureDescription": "A Gleason score of 6 is low grade, 7 is intermediate grade, and a score of 8 to 10 is high grade cancer. The Prostate Imaging Reporting and Data System (PI-RADS) is used to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious). Difference between sensitivities to identify prostate lesions. This is analyzed by the number of biopsy-proven cancerous zones (Gleason 7+) that mpMRI missed compared to PET or hrMRI (PIRADS) compared as follows:\n\nmpMRI vs hrMRI and PET (PIRADS 3-5 & Gleason 7+) mpMRI vs hrMRI or PET (PIRADS 3-5 & Gleason 7+)\n\nmpMRI vs hrMRI and PET (PIRADS 4-5 & Gleason 7+) mpMRI vs hrMRI or PET (PIRADS 4-5 & Gleason 7+)\n\nmpMRI vs hrMRI and PET (PIRADS 3-5 & Gleason 6+) mpMRI vs hrMRI or PET (PIRADS 3-5 & Gleason 6+)\n\nmpMRI vs hrMRI and PET (PIRADS 4-5 & Gleason 6+) mpMRI vs hrMRI or PET (PIRADS 4-5 & Gleason 6+)",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "Total biopsy-proven cancers (Gleason 7+)",
                            "OutcomeMeasureTimeFrame": "At time of post-imaging biopsy",
                            "OutcomeMeasureTypeUnitsAnalyzed": "Total biopsy-proven cancers (Gleason 7+)",
                            "OutcomeMeasureDenomUnitsSelected": "Total biopsy-proven cancers (Gleason 7+)",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "18F-Fluciclovine",
                                        "OutcomeGroupDescription": "10mCi +/-20% 18F-fluciclovine injection\n\n18F-Fluciclovine: Imaging (comparing standard and experimental high resolution diffusion-weighted imaging [DWI] MRI with 18F-Fluciclovine)\n\nPrior to HIFU therapy, all subjects undergo mapping MRI using both standard mpMRI and experimental diffusion-weighted imaging (DWI) PET-hrMRI with 18F-Fluciclovine. PET scans involve injection of the radioisotope or tracer, where all subjects will receive 10mCi +/-20% 18F-fluciclovine injection, diluted up to 10mL injected via the IV, as an IV bolus injection followed by 10mL flush with normal saline solution."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "13"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeDenomUnits": "Total biopsy-proven cancers (Gleason 7+)",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "20"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "Number of biopsy-proven cancers (Gleason 7+) that mpMRI missed compared to PET or hrMRI (PIRADS 3-5)",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Number of biopsy-proven cancers (Gleason 7+) that mpMRI missed compared to PET & hrMRI (PIRADS 3-5)",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Number of biopsy-proven cancers (Gleason 7+) that mpMRI missed compared to PET or hrMRI (PIRADS 4-5)",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Number of biopsy-proven cancers (Gleason 7+) that mpMRI missed compared to PET & hrMRI (PIRADS 4-5)",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeAnalysisList": {
                                "OutcomeAnalysis": [
                                    {
                                        "OutcomeAnalysisGroupIdList": {
                                            "OutcomeAnalysisGroupId": [
                                                "OG000"
                                            ]
                                        },
                                        "OutcomeAnalysisGroupDescription": "mpMRI vs hrMRI and PET (PIRADS 3-5 & Gleason 7+)",
                                        "OutcomeAnalysisNonInferiorityType": "Superiority",
                                        "OutcomeAnalysisPValue": "0.096",
                                        "OutcomeAnalysisPValueComment": "mpMRI vs hrMRI and PET (PIRADS 3-5 & Gleason 7+)",
                                        "OutcomeAnalysisStatisticalMethod": "Durkalski's Chi-square test",
                                        "OutcomeAnalysisParamType": "Sensitivity",
                                        "OutcomeAnalysisParamValue": "0.35",
                                        "OutcomeAnalysisCIPctValue": "95",
                                        "OutcomeAnalysisCINumSides": "2-Sided",
                                        "OutcomeAnalysisCILowerLimit": "0.26",
                                        "OutcomeAnalysisCIUpperLimit": "0.65",
                                        "OutcomeAnalysisEstimateComment": "We did not present standard deviation as the variability is already incorporated in the provided confidence interval."
                                    },
                                    {
                                        "OutcomeAnalysisGroupIdList": {
                                            "OutcomeAnalysisGroupId": [
                                                "OG000"
                                            ]
                                        },
                                        "OutcomeAnalysisGroupDescription": "mpMRI vs hrMRI or PET (PIRADS 3-5 & Gleason 7+)",
                                        "OutcomeAnalysisNonInferiorityType": "Superiority",
                                        "OutcomeAnalysisPValue": "0.317",
                                        "OutcomeAnalysisPValueComment": "mpMRI vs hrMRI or PET (PIRADS 3-5 & Gleason 7+)",
                                        "OutcomeAnalysisStatisticalMethod": "Durkalski's Chi-square test",
                                        "OutcomeAnalysisParamType": "Sensitivity",
                                        "OutcomeAnalysisParamValue": "0.60",
                                        "OutcomeAnalysisCIPctValue": "95",
                                        "OutcomeAnalysisCINumSides": "2-Sided",
                                        "OutcomeAnalysisCILowerLimit": "0.46",
                                        "OutcomeAnalysisCIUpperLimit": "0.90",
                                        "OutcomeAnalysisEstimateComment": "We did not present standard deviation as the variability is already incorporated in the provided confidence interval."
                                    },
                                    {
                                        "OutcomeAnalysisGroupIdList": {
                                            "OutcomeAnalysisGroupId": [
                                                "OG000"
                                            ]
                                        },
                                        "OutcomeAnalysisGroupDescription": "mpMRI vs hrMRI and PET (PIRADS 4-5 & Gleason 7+)",
                                        "OutcomeAnalysisNonInferiorityType": "Superiority",
                                        "OutcomeAnalysisPValue": "0.063",
                                        "OutcomeAnalysisPValueComment": "mpMRI vs hrMRI and PET (PIRADS 4-5 & Gleason 7+)",
                                        "OutcomeAnalysisStatisticalMethod": "Durkalski's Chi-square test",
                                        "OutcomeAnalysisParamType": "Sensitivity",
                                        "OutcomeAnalysisParamValue": "0.30",
                                        "OutcomeAnalysisCIPctValue": "95",
                                        "OutcomeAnalysisCINumSides": "2-Sided",
                                        "OutcomeAnalysisCILowerLimit": "0.23",
                                        "OutcomeAnalysisCIUpperLimit": "0.66",
                                        "OutcomeAnalysisEstimateComment": "We did not present standard deviation as the variability is already incorporated in the provided confidence interval."
                                    },
                                    {
                                        "OutcomeAnalysisGroupIdList": {
                                            "OutcomeAnalysisGroupId": [
                                                "OG000"
                                            ]
                                        },
                                        "OutcomeAnalysisGroupDescription": "mpMRI vs hrMRI or PET (PIRADS 4-5 & Gleason 7+)",
                                        "OutcomeAnalysisNonInferiorityType": "Superiority",
                                        "OutcomeAnalysisPValue": "0.317",
                                        "OutcomeAnalysisPValueComment": "mpMRI vs hrMRI or PET (PIRADS 4-5 & Gleason 7+)",
                                        "OutcomeAnalysisStatisticalMethod": "Durkalski's Chi-square test",
                                        "OutcomeAnalysisParamType": "Sensitivity",
                                        "OutcomeAnalysisParamValue": "0.60",
                                        "OutcomeAnalysisCIPctValue": "95",
                                        "OutcomeAnalysisCINumSides": "2-Sided",
                                        "OutcomeAnalysisCILowerLimit": "0.46",
                                        "OutcomeAnalysisCIUpperLimit": "0.90",
                                        "OutcomeAnalysisEstimateComment": "We did not present standard deviation as the variability is already incorporated in the provided confidence interval."
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Negative Biopsy Rate (Number of Participants With Negative Biopsy)",
                            "OutcomeMeasureDescription": "A Gleason score of 6 is low grade, 7 is intermediate grade, and a score of 8 to 10 is high grade cancer. The Prostate Imaging Reporting and Data System (PI-RADS) is used to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious). Following the tumor mapping study, patients with high grade disease (i.e. Gleason grade 4 or 5) in one lobe undergo hemigland or focal HIFU of that lobe. Patients would then undergo repeat prostate biopsy to assess the negative biopsy rate in the treated region.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "6 months following standard HIFU therapy",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "18F-Fluciclovine",
                                        "OutcomeGroupDescription": "10mCi +/-20% 18F-fluciclovine injection\n\n18F-Fluciclovine: Imaging (comparing standard and experimental high resolution diffusion-weighted imaging [DWI] MRI with 18F-Fluciclovine)\n\nPrior to HIFU therapy, all subjects undergo mapping MRI using both standard mpMRI and experimental diffusion-weighted imaging (DWI) PET-hrMRI with 18F-Fluciclovine. PET scans involve injection of the radioisotope or tracer, where all subjects will receive 10mCi +/-20% 18F-fluciclovine injection, diluted up to 10mL injected via the IV, as an IV bolus injection followed by 10mL flush with normal saline solution."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "13"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "11"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Rate of High Grade Cancer (Number of Patients With High Grade Cancer)",
                            "OutcomeMeasureDescription": "A Gleason score of 6 is low grade, 7 is intermediate grade, and a score of 8 to 10 is high grade cancer. The Prostate Imaging Reporting and Data System (PI-RADS) is used to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious). Following the tumor mapping study, patients with high grade disease (i.e. Gleason grade 4 or 5) in one lobe undergo hemigland or focal HIFU of that lobe. Patients would then undergo repeat prostate biopsy to assess the absence of Gleason grade 4 or 5 in the untreated region.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "6 months following standard HIFU therapy",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "18F-Fluciclovine",
                                        "OutcomeGroupDescription": "10mCi +/-20% 18F-fluciclovine injection\n\n18F-Fluciclovine: Imaging (comparing standard and experimental high resolution diffusion-weighted imaging [DWI] MRI with 18F-Fluciclovine)\n\nPrior to HIFU therapy, all subjects undergo mapping MRI using both standard mpMRI and experimental diffusion-weighted imaging (DWI) PET-hrMRI with 18F-Fluciclovine. PET scans involve injection of the radioisotope or tracer, where all subjects will receive 10mCi +/-20% 18F-fluciclovine injection, diluted up to 10mL injected via the IV, as an IV bolus injection followed by 10mL flush with normal saline solution."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "11"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "0",
                "EventsTimeFrame": "Up to 6 months following standard HIFU therapy.",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "18F-Fluciclovine",
                            "EventGroupDescription": "10mCi +/-20% 18F-fluciclovine injection\n\n18F-Fluciclovine: Imaging (comparing standard and experimental high resolution diffusion-weighted imaging [DWI] MRI with 18F-Fluciclovine)\n\nPrior to HIFU therapy, all subjects undergo mapping MRI using both standard mpMRI and experimental diffusion-weighted imaging (DWI) PET-hrMRI with 18F-Fluciclovine. PET scans involve injection of the radioisotope or tracer, where all subjects will receive 10mCi +/-20% 18F-fluciclovine injection, diluted up to 10mL injected via the IV, as an IV bolus injection followed by 10mL flush with normal saline solution.",
                            "EventGroupDeathsNumAffected": "0",
                            "EventGroupDeathsNumAtRisk": "13",
                            "EventGroupSeriousNumAffected": "1",
                            "EventGroupSeriousNumAtRisk": "13",
                            "EventGroupOtherNumAffected": "0",
                            "EventGroupOtherNumAtRisk": "13"
                        }
                    ]
                },
                "SeriousEventList": {
                    "SeriousEvent": [
                        {
                            "SeriousEventTerm": "Sepsis",
                            "SeriousEventOrganSystem": "Infections and infestations",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "2",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "13"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Urinary tract infection",
                            "SeriousEventOrganSystem": "Infections and infestations",
                            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "13"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "Yes"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Timothy Daskivich, M.D.",
                    "PointOfContactOrganization": "Cedars-Sinai Medical Center",
                    "PointOfContactEMail": "timothy.daskivich@cshs.org",
                    "PointOfContactPhone": "310-423-4700"
                }
            }
        },
        "DocumentSection": {
            "LargeDocumentModule": {
                "LargeDocList": {
                    "LargeDoc": [
                        {
                            "LargeDocTypeAbbrev": "Prot_SAP",
                            "LargeDocHasProtocol": "Yes",
                            "LargeDocHasSAP": "Yes",
                            "LargeDocHasICF": "No",
                            "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
                            "LargeDocDate": "June 17, 2019",
                            "LargeDocUploadDate": "12/17/2020 18:14",
                            "LargeDocFilename": "Prot_SAP_001.pdf"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023",
                "SubmissionTracking": {}
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000011471",
                            "ConditionMeshTerm": "Prostatic Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000005834",
                            "ConditionAncestorTerm": "Genital Neoplasms, Male"
                        },
                        {
                            "ConditionAncestorId": "D000014565",
                            "ConditionAncestorTerm": "Urogenital Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000005832",
                            "ConditionAncestorTerm": "Genital Diseases, Male"
                        },
                        {
                            "ConditionAncestorId": "D000091662",
                            "ConditionAncestorTerm": "Genital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000091642",
                            "ConditionAncestorTerm": "Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000011469",
                            "ConditionAncestorTerm": "Prostatic Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000052801",
                            "ConditionAncestorTerm": "Male Urogenital Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M14025",
                            "ConditionBrowseLeafName": "Prostatic Neoplasms",
                            "ConditionBrowseLeafAsFound": "Prostate Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4804",
                            "ConditionBrowseLeafName": "Body Weight",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8636",
                            "ConditionBrowseLeafName": "Genital Neoplasms, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M17005",
                            "ConditionBrowseLeafName": "Urogenital Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2877",
                            "ConditionBrowseLeafName": "Genital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8634",
                            "ConditionBrowseLeafName": "Genital Diseases, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2876",
                            "ConditionBrowseLeafName": "Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14023",
                            "ConditionBrowseLeafName": "Prostatic Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M26785",
                            "ConditionBrowseLeafName": "Male Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BXS",
                            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        }
                    ]
                }
            }
        }
    }
}